Data from EMA (European Medicines Agency) - Curated by EPG Health - Last updated 03 July 2018

Indication(s)

Panretin gel is indicated for the topical treatment of cutaneous lesions in patients with AIDS-related Kaposi’s sarcoma (KS) when:
- lesions are not ulcerated or lymphoedematous, and
- treatment of visceral KS is not required, and
- lesions are not responding to systemic antiretroviral therapy, and
- radiotherapy or chemotherapy are not appropriate.

Full Prescribing information

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Chronic Lymphocytic Leukaemia (CLL)

Chronic Lymphocytic Leukaemia (CLL)

Refine your knowledge of chronic lymphocytic leukaemia (CLL) with information on pathophysiology, diagnosis, treatment options and more

+ 1 more

Biosimilars Knowledge Centre

Biosimilars Knowledge Centre

What are biologics and how do they differ from small molecule medicines? Discover more about their development, as well as the manufacturing and regulatory processes in the Biosimilars in Oncology Knowledge Centre.

CDK 4/6 inhibitors in metastatic breast cancer

CDK 4/6 inhibitors in metastatic breast cancer

The CDK 4/6 Inhibitors in Metastatic Breast Cancer Learning Zone provides insights and information for metastatic breast cancer (mBC) and CDK 4/6 signalling. This includes the burden and pathophysiology of the disease, the role of CDK 4/6 in cell proliferation and an overview of the CDK 4/6 inhibitors that have been approved for the management of mBC.

Load more

Related Content

More information

Category Value
Agency product number EMEA/H/C/000279
Orphan designation No
Date First Approved 11-10-2000
Type Medicinal product subject to restricted medical prescription
Marketing authorisation holder Eisai Ltd